Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Background Recent studies indicate that short subclinical episodes of herpes simplex virus type 2 (HSV-2) are the predominant form of skin and mucosal viral shedding. We evaluated whether standard or high-dose antiviral therapy reduced the frequency of such shedding. Methods To determine whether short episodes of genital HSV shedding are suppressed on standard dose (SD) and high-dose (HD) antiviral therapy, HSV-2 seropositive, HIV seronegative persons in Seattle, WA were enrolled into three separate but complementary randomized, open-label, cross-over studies comparing 1) no medication to aciclovir 400 mg twice daily (SD-ACV), 2) valaciclovir 500 mg daily (SD-VAL) to aciclovir 800 mg three times daily (TID) (HD-ACV), and 3) SD-VAL to HD-VAL (1 gm TID). Study arms lasted 4–7 weeks, separated by one week wash-out. Participants obtained genital swabs four times daily for quantitative HSV DNA PCR. The primary endpoint was within-person comparison of shedding rate on each study arm. Results Of 113 participants randomized, 90 were eligible for analysis of the primary endpoint. Participants collected 23,605 swabs; of these 1272 (5·4%) had HSV detected. HSV shedding was significantly higher during the no medication arm (18·1% of swabs) compared with SD-ACV (1.2% of swabs, IRR=0·05, 95% CI=0·03–0·08). Breakthrough reactivations occurred on all doses (SD-ACV 1·2%, SD-VAL 5·2%, HD-ACV 4·2%, and HD-VAL 3·3% of swabs). HD-VAL was associated with less shedding compared with SD-VAL (IRR=0·54, 95% CI=0·44–0·66), likely due to more rapid clearance of mucosal HSV (4·7 logs/6 hours on HD-VAL vs. 4·4 logs/6 hours on SD-VAL, (p=0·02)). However, the annualized breakthrough episodes was similar on SD-VAL (22·6) and HD-ACV (20·2, p=0·54) and SD-VAL (14.9) and HD-VAL (16·5, p=0·34). Regardless of dose, breakthrough episodes were short (median 7–10 hours) and 80% were subclinical. Studies were not designed to make inter-trial comparisons between antiviral doses. Except for increased incidence of headaches on HD-VAL, all regimens were well-tolerated. Conclusions Short bursts of subclinical genital HSV reactivation are frequent, even during high-dose antiherpes therapy, and likely account for continued transmission of HSV-2 during suppressive antiviral therapy. More potent antiviral therapy is needed to abolish HSV-2 transmission
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Once-daily valacyclovir to reduce the risk of transmission of genital herpes.
Corey, L., Wald, A., Patel, R., Sacks, S. L., Tyring, S. K., Warren, T., Douglas, J. M., Paavonen, J., Morrow, R. A., Beutner, K. R., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035144 · Cited by 720
Self-citationBrown, Z. A., Wald, A., Morrow, R. A., Selke, S., Zeh, J., & Corey, L. (2003) · JAMA · doi:10.1001/jama.289.2.203 · Cited by 679
Self-citationAcyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2.
Celum, C., Wald, A., Lingappa, J. R., Magaret, A. S., Wang, R. S., Mugo, N., Mujugira, A., Baeten, J. M., Mullins, J. I., Hughes, J. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0904849 · Cited by 524
Self-citationCelum, C., Wald, A., Hughes, J., Sanchez, J., Reid, S., Delany-Moretlwe, S., Cowan, F., Casapia, M., Ortiz, A., Fuchs, J., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60920-4 · Cited by 449
Self-citationReitano, M., Tyring, S., Lang, W., Thoming, C., Worm, A. ‐., Borelli, S., Chambers, L. O., Robinson, J. M., Corey, L., & the International Valaciclovir HSV Study Group (1998) · The Journal of Infectious Diseases · doi:10.1086/515385 · Cited by 209
Self-citation
Cited by
Torres, N. I., Noll, K. S., Xu, S., Li, J., Huang, Q., Sinko, P. J., Wachsman, M. B., & Chikindas, M. L. (2013) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-012-9123-x · Cited by 122
“Considering the incidence of HSV infections and the issues regarding the clinical approved antiherpetic drugs, such as the reported emergence of ACV, PCV and FOS resistant mutants and that it has been recently shown that the available antiviral treatment of herpetic infections fail to reduce HSV and HIV transmission,…”
Antiherpes simplex virus type 2 activity of the antimicrobial peptide subtilosin
Quintana, V. M., Torres, N. I., Wachsman, M. B., Sinko, P. J., Castilla, V., & Chikindas, M. (2014) · Journal of Applied Microbiology · doi:10.1111/jam.12618 · Cited by 69
Keratinocytes produce IL-17c to protect peripheral nervous systems during human HSV-2 reactivation
Peng, T., Chanthaphavong, R. S., Sun, S., Trigilio, J. A., Phasouk, K., Jin, L., Layton, E. D., Li, A. Z., Correnti, C. E., De van der Schueren, W., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20160581 · Cited by 60
Self-citation
Metadata
- Authors
- Johnston, C., Saracino, M., Kuntz, S., Magaret, A., Selke, S., Huang, M.-L., Schiffer, J. T., Koelle, D. M., Corey, L., & Wald, A.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2012-02
- Volume
- 379
- Issue
- 9816
- Pages
- 641-647
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2120210643
- Cited by
- 126
- References
- 5
- FWCI
- 10.34
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials. https://app.cochat.ai/papers/10.1016/s0140-6736(11)61750-9
- The paper
- Johnston, C., Saracino, M., Kuntz, S., Magaret, A., Selke, S., Huang, M.-L., Schiffer, J. T., Koelle, D. M., Corey, L., & Wald, A. (2012). Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials. The Lancet. https://doi.org/10.1016/s0140-6736(11)61750-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.